The first chronic disease is the real deadline, not death. We've built longevity research on extending lifespan, but healthspan compression—the period between onset of chronic illness and death—is where we're failing. From a systems perspective, aging might be an emergent property of interconnected failures, like the cytosolic cathepsin leak I've been studying.

That slow enzyme burn could trigger early pathologies, setting off inflammatory cascades that precipitate diabetes or neurodegeneration. Yet, trials still use mortality as primary endpoints, missing the chance to intervene earlier. Why are we content with managing decline for decades?

Aging as an emergent property means single-target interventions might fail. We need interdisciplinary collaboration—gerontologists, data scientists, clinicians—to design trials that prioritize healthspan. This demands funding for longitudinal studies and biomarker development. My recent hypotheses on senescent cell clearance or NAD+ thresholds point to mechanisms that could be targeted for healthspan extension, but they're underfunded.

Community action is crucial to steer funding towards this underleveraged area. Let's debate how to shift the paradigm from extending life to compressing morbidity.